{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:35:23Z","timestamp":1759494923602},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"20","license":[{"start":{"date-parts":[[2008,5,15]],"date-time":"2008-05-15T00:00:00Z","timestamp":1210809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2008,5,15]],"date-time":"2008-05-15T00:00:00Z","timestamp":1210809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1038\/gt.2008.81","type":"journal-article","created":{"date-parts":[[2008,5,15]],"date-time":"2008-05-15T11:48:32Z","timestamp":1210852112000},"page":"1351-1360","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunogenicity and safety profiles of genetic vaccines against human Her-2\/neu in cynomolgus monkeys"],"prefix":"10.1038","volume":"15","author":[{"given":"H-J","family":"Ko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y-J","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y-S","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J-M","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S-H","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J-G","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S-M","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J-A","family":"Chae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C-Y","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P-S","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C-Y","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,5,15]]},"reference":[{"key":"BFgt200881_CR1","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/bjc.1991.100","volume":"63","author":"WJ Gullick","year":"1991","unstructured":"Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991; 63: 434\u2013438.","journal-title":"Br J Cancer"},{"key":"BFgt200881_CR2","first-page":"16","volume":"54","author":"ML Disis","year":"1994","unstructured":"Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B et al. Existent T-cell and antibody immunity to HER-2\/neu protein in patients with breast cancer. Cancer Res 1994; 54: 16\u201320.","journal-title":"Cancer Res"},{"key":"BFgt200881_CR3","first-page":"732","volume":"58","author":"P Brossart","year":"1998","unstructured":"Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L et al. Her-2\/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 1998; 58: 732\u2013736.","journal-title":"Cancer Res"},{"key":"BFgt200881_CR4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/ijc.20232","volume":"111","author":"SY Chang","year":"2004","unstructured":"Chang SY, Lee KC, Ko SY, Ko HJ, Kang CY . Enhanced efficacy of DNA vaccination against Her-2\/neu tumor antigen by genetic adjuvants. Int J Cancer 2004; 111: 86\u201395.","journal-title":"Int J Cancer"},{"key":"BFgt200881_CR5","doi-asserted-by":"publisher","first-page":"6843","DOI":"10.1158\/0008-5472.CAN-06-0889","volume":"66","author":"Y Chung","year":"2006","unstructured":"Chung Y, Kim BS, Kim YJ, Ko HJ, Ko SY, Kim DH et al. CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo. Cancer Res 2006; 66: 6843\u20136850.","journal-title":"Cancer Res"},{"key":"BFgt200881_CR6","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0264-410X(02)00470-X","volume":"21","author":"JY Lee","year":"2003","unstructured":"Lee JY, Kim DH, Chung Y, Shin SU, Kang CY . Comparison of the antitumor efficacies of Her-2\/neu DNA vaccines inducing contrasting IgG immunity but comparable CTL activity in mice. Vaccine 2003; 21: 521\u2013531.","journal-title":"Vaccine"},{"key":"BFgt200881_CR7","doi-asserted-by":"publisher","first-page":"7477","DOI":"10.1158\/0008-5472.CAN-06-4639","volume":"67","author":"HJ Ko","year":"2007","unstructured":"Ko HJ, Kim YJ, Kim YS, Chang WS, Ko SY, Chang SY et al. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res 2007; 67: 7477\u20137486.","journal-title":"Cancer Res"},{"key":"BFgt200881_CR8","first-page":"2782","volume":"8","author":"RM Conry","year":"2002","unstructured":"Conry RM, Curiel DT, Strong TV, Moore SE, Allen KO, Barlow DL et al. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res 2002; 8: 2782\u20132787.","journal-title":"Clin Cancer Res"},{"key":"BFgt200881_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/ijc.20569","volume":"113","author":"CL Smith","year":"2005","unstructured":"Smith CL, Dunbar PR, Mirza F, Palmowski MJ, Shepherd D, Gilbert SC et al. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer 2005; 113: 259\u2013266.","journal-title":"Int J Cancer"},{"key":"BFgt200881_CR10","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659\u20131672.","journal-title":"N Engl J Med"},{"key":"BFgt200881_CR11","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa053028","volume":"354","author":"H Joensuu","year":"2006","unstructured":"Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809\u2013820.","journal-title":"N Engl J Med"},{"key":"BFgt200881_CR12","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1158\/1078-0432.CCR-06-2083","volume":"13","author":"Y Dang","year":"2007","unstructured":"Dang Y, Knutson KL, Goodell V, dela Rosa C, Salazar LG, Higgins D et al. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming. Clin Cancer Res 2007; 13: 1883\u20131891.","journal-title":"Clin Cancer Res"},{"key":"BFgt200881_CR13","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1200\/JCO.2002.06.171","volume":"20","author":"ML Disis","year":"2002","unstructured":"Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA et al. Generation of T-cell immunity to the HER-2\/neu protein after active immunization with HER-2\/neu peptide-based vaccines. J Clin Oncol 2002; 20: 2624\u20132632.","journal-title":"J Clin Oncol"},{"key":"BFgt200881_CR14","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.1200\/JCO.2006.10.5718","volume":"25","author":"JW Park","year":"2007","unstructured":"Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R . Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J Clin Oncol 2007; 25: 3680\u20133687.","journal-title":"J Clin Oncol"},{"key":"BFgt200881_CR15","first-page":"3569","volume":"60","author":"RT Reilly","year":"2000","unstructured":"Reilly RT, Gottlieb MB, Ercolini AM, Machiels JP, Kane CE, Okoye FI et al. HER-2\/neu is a tumor rejection target in tolerized HER-2\/neu transgenic mice. Cancer Res 2000; 60: 3569\u20133576.","journal-title":"Cancer Res"},{"key":"BFgt200881_CR16","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1158\/0008-5472.1071.65.3","volume":"65","author":"SM Pupa","year":"2005","unstructured":"Pupa SM, Iezzi M, Di Carlo E, Invernizzi A, Cavallo F, Meazza R et al. Inhibition of mammary carcinoma development in HER-2\/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Res 2005; 65: 1071\u20131078.","journal-title":"Cancer Res"},{"key":"BFgt200881_CR17","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/ijc.22274","volume":"120","author":"P Gallo","year":"2007","unstructured":"Gallo P, Dharmapuri S, Nuzzo M, Maldini D, Cipriani B, Forni G et al. Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB\/neuT transgenic mice. Int J Cancer 2007; 120: 574\u2013584.","journal-title":"Int J Cancer"},{"key":"BFgt200881_CR18","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1146\/annurev.immunol.18.1.927","volume":"18","author":"S Gurunathan","year":"2000","unstructured":"Gurunathan S, Klinman DM, Seder RA . DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000; 18: 927\u2013974.","journal-title":"Annu Rev Immunol"},{"key":"BFgt200881_CR19","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1002\/ijc.22555","volume":"120","author":"L Aurisicchio","year":"2007","unstructured":"Aurisicchio L, Mennuni C, Giannetti P, Calvaruso F, Nuzzo M, Cipriani B et al. Immunogenicity and safety of a DNA prime\/adenovirus boost vaccine against rhesus CEA in nonhuman primates. Int J Cancer 2007; 120: 2290\u20132300.","journal-title":"Int J Cancer"},{"key":"BFgt200881_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2174\/1566523013348931","volume":"1","author":"V Bronte","year":"2001","unstructured":"Bronte V . Genetic vaccination for the active immunotherapy of cancer. Curr Gene Ther 2001; 1: 53\u2013100.","journal-title":"Curr Gene Ther"},{"key":"BFgt200881_CR21","doi-asserted-by":"publisher","first-page":"4497","DOI":"10.1038\/sj.onc.1204542","volume":"20","author":"JJ Kim","year":"2001","unstructured":"Kim JJ, Yang JS, Nottingham LK, Tang W, Dang K, Manson KH et al. Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen. Oncogene 2001; 20: 4497\u20134506.","journal-title":"Oncogene"},{"key":"BFgt200881_CR22","first-page":"2903","volume":"4","author":"RM Conry","year":"1998","unstructured":"Conry RM, White SA, Fultz PN, Khazaeli MB, Strong TV, Allen KO et al. Polynucleotide immunization of nonhuman primates against carcinoembryonic antigen. Clin Cancer Res 1998; 4: 2903\u20132912.","journal-title":"Clin Cancer Res"},{"key":"BFgt200881_CR23","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0093-7754(03)00356-7","volume":"30","author":"JD Wolchok","year":"2003","unstructured":"Wolchok JD, Gregor PD, Nordquist LT, Slovin SF, Scher HI . DNA vaccines: an active immunization strategy for prostate cancer. Semin Oncol 2003; 30: 659\u2013666.","journal-title":"Semin Oncol"},{"key":"BFgt200881_CR24","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.4049\/jimmunol.178.3.1767","volume":"178","author":"N Koizumi","year":"2007","unstructured":"Koizumi N, Yamaguchi T, Kawabata K, Sakurai F, Sasaki T, Watanabe Y et al. Fiber-modified adenovirus vectors decrease liver toxicity through reduced IL-6 production. J Immunol 2007; 178: 1767\u20131773.","journal-title":"J Immunol"},{"key":"BFgt200881_CR25","doi-asserted-by":"publisher","first-page":"7478","DOI":"10.1128\/JVI.79.12.7478-7491.2005","volume":"79","author":"DM Shayakhmetov","year":"2005","unstructured":"Shayakhmetov DM, Gaggar A, Ni S, Li ZY, Lieber A . Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol 2005; 79: 7478\u20137491.","journal-title":"J Virol"},{"key":"BFgt200881_CR26","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.4049\/jimmunol.167.8.4286","volume":"167","author":"MH Ryan","year":"2001","unstructured":"Ryan MH, Bristol JA, McDuffie E, Abrams SI . Regression of extensive pulmonary metastases in mice by adoptive transfer of antigen-specific CD8(+) CTL reactive against tumor cells expressing a naturally occurring rejection epitope. J Immunol 2001; 167: 4286\u20134292.","journal-title":"J Immunol"},{"key":"BFgt200881_CR27","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/nrc1167","volume":"3","author":"ME Dudley","year":"2003","unstructured":"Dudley ME, Rosenberg SA . Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3: 666\u2013675.","journal-title":"Nat Rev Cancer"},{"key":"BFgt200881_CR28","first-page":"1014","volume":"8","author":"KL Knutson","year":"2002","unstructured":"Knutson KL, Schiffman K, Cheever MA, Disis ML . Immunization of cancer patients with a HER-2\/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 2002; 8: 1014\u20131018.","journal-title":"Clin Cancer Res"},{"key":"BFgt200881_CR29","doi-asserted-by":"publisher","first-page":"7470","DOI":"10.1158\/1078-0432.CCR-05-0235","volume":"11","author":"MT Hueman","year":"2005","unstructured":"Hueman MT, Dehqanzada ZA, Novak TE, Gurney JM, Woll MM, Ryan GB et al. Phase I clinical trial of a HER-2\/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients. Clin Cancer Res 2005; 11: 7470\u20137479.","journal-title":"Clin Cancer Res"},{"key":"BFgt200881_CR30","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.4049\/jimmunol.165.7.4105","volume":"165","author":"Q Sun","year":"2000","unstructured":"Sun Q, Burton RL, Dai LJ, Britt WJ, Lucas KG . B lymphoblastoid cell lines as efficient APC to elicit CD8+ T cell responses against a cytomegalovirus antigen. J Immunol 2000; 165: 4105\u20134111.","journal-title":"J Immunol"},{"key":"BFgt200881_CR31","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/ijc.20779","volume":"114","author":"SJ Youde","year":"2005","unstructured":"Youde SJ, McCarthy CM, Thomas KJ, Smith KL, Man S . Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line. Int J Cancer 2005; 114: 606\u2013612.","journal-title":"Int J Cancer"},{"key":"BFgt200881_CR32","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.4049\/jimmunol.164.6.3102","volume":"164","author":"K Kusakabe","year":"2000","unstructured":"Kusakabe K, Xin KQ, Katoh H, Sumino K, Hagiwara E, Kawamoto S et al. The timing of GM-CSF expression plasmid administration influences the Th1\/Th2 response induced by an HIV-1-specific DNA vaccine. J Immunol 2000; 164: 3102\u20133111.","journal-title":"J Immunol"},{"key":"BFgt200881_CR33","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/10245330410001701549","volume":"9","author":"DZ Chang","year":"2004","unstructured":"Chang DZ, Lomazow W, Joy Somberg C, Stan R, Perales MA . Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines. Hematology 2004; 9: 207\u2013215.","journal-title":"Hematology"},{"key":"BFgt200881_CR34","doi-asserted-by":"publisher","first-page":"6337","DOI":"10.1158\/0008-5472.CAN-04-0757","volume":"64","author":"P Serafini","year":"2004","unstructured":"Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I . High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004; 64: 6337\u20136343.","journal-title":"Cancer Res"},{"key":"BFgt200881_CR35","doi-asserted-by":"publisher","first-page":"8896","DOI":"10.1158\/0008-5472.CAN-05-1734","volume":"65","author":"MM Queen","year":"2005","unstructured":"Queen MM, Ryan RE, Holzer RG, Keller-Peck CR, Jorcyk CL . Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Res 2005; 65: 8896\u20138904.","journal-title":"Cancer Res"},{"key":"BFgt200881_CR36","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nm1519","volume":"13","author":"BK Park","year":"2007","unstructured":"Park BK, Zhang H, Zeng Q, Dai J, Keller ET, Giordano T et al. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 2007; 13: 62\u201369.","journal-title":"Nat Med"},{"key":"BFgt200881_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc1252","volume":"4","author":"G Dranoff","year":"2004","unstructured":"Dranoff G . Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004; 4: 11\u201322.","journal-title":"Nat Rev Cancer"},{"key":"BFgt200881_CR38","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/JCO.2006.08.5829","volume":"25","author":"P Filipazzi","year":"2007","unstructured":"Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007; 25: 2546\u20132553.","journal-title":"J Clin Oncol"},{"key":"BFgt200881_CR39","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1016\/j.ejca.2007.06.024","volume":"43","author":"MA de Korte","year":"2007","unstructured":"de Korte MA, de Vries EG, Lub-de Hooge MN, Jager PL, Gietema JA, van der Graaf WT et al. Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 2007; 43: 2046\u20132051.","journal-title":"Eur J Cancer"},{"key":"BFgt200881_CR40","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1182\/blood-2004-06-2410","volume":"105","author":"ME Lutsiak","year":"2005","unstructured":"Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H . Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005; 105: 2862\u20132868.","journal-title":"Blood"},{"key":"BFgt200881_CR41","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1073\/pnas.93.3.1320","volume":"93","author":"S Miyake","year":"1996","unstructured":"Miyake S, Makimura M, Kanegae Y, Harada S, Sato Y, Takamori K et al. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc Natl Acad Sci USA 1996; 93: 1320\u20131324.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFgt200881_CR42","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/ijc.20536","volume":"113","author":"P Gallo","year":"2005","unstructured":"Gallo P, Dharmapuri S, Nuzzo M, Maldini D, Iezzi M, Cavallo F et al. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int J Cancer 2005; 113: 67\u201377.","journal-title":"Int J Cancer"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/gt200881.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gt200881","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gt200881.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T10:40:44Z","timestamp":1684406444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/gt200881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,15]]},"references-count":42,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["BFgt200881"],"URL":"https:\/\/doi.org\/10.1038\/gt.2008.81","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,15]]},"assertion":[{"value":"19 November 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2008","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2008","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2008","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}